Macquarie Group’s BridgeBio Pharma BBIO Stock Holding History

Macquarie Group’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24K	Buy	+322	New	+$22.6K	﹤0.01%	882
2025 Q4	–	Sell	-1,933,096	Closed	-$100M	–	926
2025 Q3	$100M	Sell	1,933,096 -162,139	-8%	-$7.91M	0.12%	227
2025 Q2	$90.5M	Buy	2,095,235 +2,003,713	+2,189%	+$72.9M	0.11%	261
2025 Q1	$3.16M	Buy	+91,522	New	+$3.09M	﹤0.01%	1091
2022 Q4	–	Sell	-1,210	Closed	-$18K	–	1785
2022 Q3	$18K	Sell	1,210 -589	-33%	-$6.12K	﹤0.01%	2227
2022 Q2	$16K	Hold	1,799	–	–	﹤0.01%	2359
2022 Q1	$18K	Hold	1,799	–	–	﹤0.01%	2409
2021 Q4	$30K	Hold	1,799	–	–	﹤0.01%	2296
2021 Q3	$84K	Hold	1,799	–	–	﹤0.01%	2036
2021 Q2	$110K	Hold	1,799	–	–	﹤0.01%	1946
2021 Q1	$111K	Buy	+1,799	New	+$118K	﹤0.01%	1873

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Macquarie Group's BBIO Position: Q2 2026 in Review

Macquarie Group opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 322 shares worth $24K. The stake represents ﹤0.01% of the portfolio and ranks #882 among its holdings. This is a return to the name: Macquarie Group previously reported a position in BBIO as recently as Q3 2025.

Macquarie Group first reported a position in BBIO in Q1 2021 and has held it in 11 quarters since. The position peaked at $100M in Q3 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Macquarie Group held 322 shares of BridgeBio Pharma worth $24K as of Q2 2026.
BridgeBio Pharma was a new Macquarie Group position in Q2 2026.
BridgeBio Pharma made up ﹤0.01% of Macquarie Group's portfolio in Q2 2026, its #882 holding.
Macquarie Group first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 11 quarters since.
Macquarie Group's BridgeBio Pharma position peaked at $100M in Q3 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Macquarie Group's 13F filing for Q2 2026, filed 14 Aug 2026.